Objective. We aimed to analyse the effect of maintenance therapy after induction on the outcomes of adult patients with primary angiitis of the CNS (PACNS).
Introduction
Primary angiitis of the CNS (PACNS) is a rare inflammatory condition affecting CNS vessels [15] . Over the last decade, two large adult cohorts and one paediatric cohort have been reported, describing different forms of the disease [610] . However, due to the rarity of the condition, no prospective therapeutic trials have been conducted to determine the best strategies for the management of PACNS. Its treatment is by default often similar to what is done in systemic vasculitides, especially ANCA-associated vasculitis (AAV). For the latter, therapeutic management relies on an induction period with high-dose glucocorticoids (GCs), often combined with an immunosuppressant [CYC or rituximab (RTX)]. Once remission is achieved, maintenance therapy is given to keep the disease under control and to limit the risk of relapse [1113] . In a previous study on PACNS, we showed that induction treatment with GC combined with an immunosuppressant (CYC in most cases) in severe cases leads to disease remission in most patients. However, outcome after remission is uncertain and relapses or disabilities may complicate the course of the disease [7] . The effect of maintenance therapy, following induction, has not been evaluated thoroughly in adults with PACNS. In the absence of validated therapeutic guidelines to date, the role of maintenance therapy in PACNS remains unclear and is usually provided depending only on the standard practice/preferences/choice of the treating physicians. We aimed to determine whether or not the prescription of maintenance therapy after induction improves survival, relapse rates and functional status in patients from the French PACNS cohort.
Methods

Patients
We initiated a cohort of patients with confirmed diagnoses of PACNS (COVAC': COhort of patients with primary VAsculitis of the Central Nervous System) in 2010 in France, using the well-established networks of the French Vasculitis Study Group, French NeuroVascular Society and National Society of Internal Medicine. The cohort now includes 109 patients (a report on the first 52 patients was published in 2014 [7] ), 42 and 67 from Internal Medicine and Neurology departments, respectively. All included patients were age >18 years, had at least 6 months' follow-up from diagnosis (unless they had died before) and had an extensive work-up to exclude systemic vasculitis, CTD, infections, malignancy or any other diseases possibly involving CNS and mimicking PACNS. They all demonstrated CNS vessel involvement on biopsy, digital subtraction angiography (DSA) and/or magnetic resonance angiography (MRA). We excluded patients with a presentation compatible with cerebral vasculopathy (unless they had a positive biopsy), such as atherosclerosis or reversible cerebral vasoconstriction syndrome.
For this study, we selected those patients from the cohort who had achieved remission with their induction treatment, with follow-up 512 months and with full information on health status and treatments at last follow-up available. We also included patients who died before the 12 months follow-up period only if they had achieved remission after the induction period. We analysed them according to whether or not they had received maintenance therapy with an immunosuppressant (other than GC) after their induction treatment in order to keep the disease in remission. Patients who had received some maintenance treatment only after a relapse were initially classified in the group without maintenance, and were also re-analysed separately. Study visits were not scheduled during follow-up, but enrolled patients were seen at least every 6 months in their respective hospitals.
This cohort was funded by a grant from the French Ministry of Health (COhort of patients with primary VAsculitis of the Central Nervous System, 2009 PHRC 08017). This study was conducted in compliance with good clinical practices and the Declaration of Helsinki. Inclusion in the cohort required informed consent from patients and the cohort study was approved by the Paris-Cochin institutional review board (CPPRB) (No. 12541).
Study variables and definition
Using a standardized record, the characteristics of each patient were retrieved from their medical records, as described earlier [7] . Demographics, past medical history, clinical symptoms since disease onset, laboratory test results, results of neuroimaging studies and treatments were collected. When available, cerebrospinal fluid (CSF) findings were also collected. We recorded the use and duration of intake of GC throughout follow-up for each patient and whether an additional immunosuppressant drug, other than GC, was given for maintenance once remission had been achieved. Abnormal CSF was defined as a leucocyte count >5/mm 3 and/or a protein concentration >0.5 g/ml. CNS histology results were gathered from the pathology reports. Positive histology was defined as a transmural vascular infiltrate, with or without granulomatous inflammation, lymphocytic infiltrate and/or necrosis. Neuroimaging studies were centrally reviewed by two neuroradiologists (G.B. and O.N.), unaware of the clinical symptoms. Results of MRI with T1-weighted, T2-weighted, fluid-attenuated inversion recovery, T1-weighted with gadolinium injection, gradient-echo T2*-weighted and diffusion-weighted imaging with apparent diffusion coefficient mapping were collected, when available. Acute ischaemic lesions corresponded to high intensities on diffusion weighted imaging with restricted diffusion on apparent diffusion coefficient mapping; haemorrhages appeared as hypointense signals on T2*-weighted sequences. The presence or absence of multiple smooth-wall segmental narrowing, dilation or occlusions was also recorded.
As carried out previously, we differentiated large-, medium-, and small-sized vessels [7, 8, 10] . Intra-cranial internal carotid and proximal anterior (A1), middle (M1) www.rheumatology.oxfordjournals.org and posterior (P1) cerebral arteries were considered as large; second divisions (A2, M2, P2) and subsequent branches (>A2, >M2, >P2) were considered mediumand small-sized, respectively. Small-vessel PACNS was diagnosed based on both positive biopsy and negative neurovascular imaging.
Updated information for each patient was collected by contacting the referring physician and/or patient's general practitioner (in April and May 2016). Disease status at last follow-up, treatments received and history or not of disease relapse were collected for all included patients. Functional status was evaluated using the modified Rankin scale (mRS; calculated on the basis of medical charts for patients enrolled retrospectively; 0 = no neurological deficits; 1 = no significant disability, despite symptoms; 2 = slight disability; 3 = moderate disability; 4 = moderately severe disability; 5 = severe disability; and 6 = death) [14] . mRS was recorded at different time points: before starting any therapy, in months 6 and 12, then every year until last follow-up. Remission, as assessed and determined by the patients' treating physicians, was defined as the absence of disease activity attributable to PACNS (i.e. no worsening or new clinical symptoms) after at least three consecutive months of induction therapy. Relapse was defined as the re-occurrence of neurological symptoms associated or not with neuroimaging worsening leading to treatment increase. A good outcome was defined as relapse-free survival and good functional status (mRS 4 2) at last follow-up. Poor outcomes were defined as death or occurrence of relapse or an mRS > 2 at last follow-up.
Statistical analyses
Categorical variables are expressed as a number (%) and quantitative variables as median [range] . Categorical variables were analysed using the chi-square or Fisher's exact test, and quantitative variables using Wilcoxon's rank-sum test. Repetitive mRS over time among the same subjects was compared using Wilcoxon's matched-pairs signed rank test for quantitative variables.
Multivariate logistic regression analysis was performed to determine factors independently associated with good outcomes and those associated with good functional status using variables that reached P < 0.2 in univariate analysis. A Cox proportional hazards model was used to assess factors associated with relapse, using variables that reached P < 0.2 in univariate analysis. We analysed relapse-free survival using life tables and the KaplanMeier method, and these were compared with log-rank tests. Statistical analyses were computed using JMP 9.0.1 (SAS Institute Inc., Cary, NC, USA). A P 4 0.05 defined statistical significance.
Results
Patient cohort
Twelve of the 109 patients entering the cohort at the time of this study were excluded from this analysis, as 8 had <12 months follow-up and 4 died in the first few weeks following diagnosis before achieving remission. The characteristics of the 97 patients included in this study [46 (47%) female, median age: 46 (1878) years at diagnosis] are shown in Table 1 . In this study, 30 patients were enrolled from Internal Medicine departments whereas the 67 others were enrolled from Neurology departments. Diagnosis of PACNS was confirmed on the basis of the biopsy findings in 30 (31%) patients, and on clinical, biological and DSA findings in 59 (61%) or MRA in the remaining 8 (8%).
Treatment
The treatments are given in Table 1 . Induction treatment consisted of GC in 95 (98%) patients, combined with an immunosuppressant in 80 patients (82%; CYC in 78 and RTX in 2). The 2 patients who did not receive GC had six and eight pulses of CYC. Altogether, among the 80 patients treated with CYC, 77 received IV pulses [median of six (212) pulses over 6 (210) months], while the other 3 received daily oral CYC. The 15 patients who received GC alone did not differ significantly from those who also received CYC, in terms of their disease presentation at onset (clinical, biological and radiological). Thirty-eight patients received concomitant aspirin.
Maintenance therapy (i.e. with an immunosuppressant other than GC) was prescribed after induction treatment in 48 patients (49%, 24 Internal Medicine and 24 from Neurology), following CYC in 42 of them. AZA (2 mg/kg/ day), MMF (2 g/day) and MTX (0.30.5 mg/kg/week) were chosen in 38, 4 and 6 patients, respectively. Maintenance drugs were started at a median time of 4 (318) months after GC initiation (and 46 weeks after the last pulses of CYC in the 2 patients who did not receive GC) and were prescribed for a median duration of 24 (672) months.
No differences were observed between patients who received maintenance drugs or not, in terms of their clinical symptoms at disease onset (including disease severity), biological parameters, radiological findings or induction treatments (Table 1) .
Outcomes
With a median follow-up of 55 (5198) months, 42 (43%) patients had good outcomes, that is, survived without relapse and with an mRS4 2 at last follow-up ( Table 2 ). As shown in Fig. 1 , such good outcomes were observed in 32 (67%) patients who had received maintenance therapy and in 10 (20%) who had not (P < 0.0001).
Thirty-two (33%) patients relapsed, including 10/48 (21%) who had received maintenance therapy and 22/49 (45%) who had not (P = 0.01). Relapses occurred 16 (584) months after initiation of induction treatment (Table 3) . AZA was given to 5 of the 10 relapsing patients who had received maintenance (3 of them had discontinued it prior to relapse [4 (36) months before]), MMF to 3 patients (discontinued in 1 of them 5 months prior to relapse) and MTX to 2 patients (discontinued in both, 3 and 4 months before the relapse).
Overall, 17 (53%) of all relapsers were still treated at the time of the relapses (13 with GC alone, 3 with both GC and another maintenance immunosuppressant and 1 with MMF alone), and 6 had discontinued maintenance prior to the relapse. GC was resumed or increased for all relapsing patients, and 13 (including 6 who previously had CYC) received induction, with CYC in 7 and RTX in 6. Ten patients, who did not have maintenance treatment initially, were then given the treatment after their relapses (AZA in 8, MMF in 1, RTX in 1). Six of these patients Good outcome is defined as survival with no relapse and with a good functional status (modified Rankin Scale 4 2) at last follow-up. relapsed once again (3 with GC and AZA, 3 with GC alone) and 1 relapsed 53 times.
Four (4%) patients who had initially achieved remission after induction treatment {with a combination of glucocorticoids [75 (60120) mg/day] and CYC [6 (2-6) infusions]} died during relapse, at a median of 15 (537) months after GC onset. All of them had received i.v. CYC and were on GC at the time of their relapse, and one was also on AZA for maintenance. Relapse-free survival was better in patients with maintenance therapy compared with those who received no maintenance ( Fig.  2 ; log-rank test = 0.02).
At last follow-up, 57 (59%) patients had an mRS4 2 (supplementary Table S1 , available at Rheumatology Online) including 38/48 (79%) patients who had received maintenance therapy vs 19/49 (39%) who had not (P < 0.0001). Seventy-five patients (77%; 79% of patients who received maintenance therapy and 75% of patients who had not, P = 34) had discontinued GC after a median duration of 25 (3198) months. Patients who received maintenance therapy were on significantly lower daily doses of GC at 6, 12 and 18 months, but we did not observe any difference at last follow-up regarding the duration of GC or the number of patients who had discontinued GC.
Twenty-four (25%) patients were still treated (15 on GC alone, 5 on GC and AZA and 4 on AZA alone). At last follow-up, among the 32 relapsing patients, no difference was observed regarding functional status between the 10 patients who started maintenance therapy after relapse compared with the 22 who did not [median mRS: 2.5 (14) vs 3 (06), P = 0.57].
Other factors influencing outcomes
In the multivariate analysis, maintenance therapy was the only predictor of good outcomes [odds ratio (OR) = 7.8 (95% CI 3.2120.36), P < 0.0001; Table 4 ].
Relapsing patients showed more gadolinium-enhanced lesions on MRI (P = 0.004) and more isolated small-vessel PACNS (P = 0.002) than non-relapsing patients (Table 3) . Conversely, they also had lower mRS before starting any treatment (P = 0.007), less severe speech disorder (P = 0.02), less vascular stenosis on MRA and DSA (P = 0.0007 and P = 0.005, respectively) and they received maintenance therapy less often (P = 0.01). Induction treatments were not different in patients with or without relapse. In the multivariate analysis (supplementary Table  S2 , available at Rheumatology Online), the best predictor of relapse was the isolated involvement of small vessels [hazard ratio (HR) = 2.38 (1.164.80), P = 0.02]. Maintenance therapy and high mRS before starting treatment were also protective factors against relapse [HR = 0.37 (0.160.79), P = 0.01; HR = 0.59 (0.410.85), P = 0.005, respectively]. Initial dose and duration of GC or administration of aspirin did not influence any of the study endpoints.
Comparison of patients with good and poor functional status at last follow-up indicated that the three main parameters significantly associated with mRS4 2 were a lower mRS before starting any treatment (P = 0.002), less abnormal CSF analysis (P = 0.007) at diagnosis and prescription of maintenance therapy (P < 0.0001) (supplementary Table S1 , available at Rheumatology Online). In the multivariate analysis (supplementary Table S3 , available at Rheumatology Online), maintenance therapy was the strongest predictor of good functional status at last follow-up [OR = 8.17 (3.0324.91), P < 0.0001]. In addition, lower mRS before starting treatment and headaches at disease onset were associated with good functional status [OR = 2.19 (1.293.98), P = 0.006 and OR = 3.79 (1.4111.28), P = 0.01, respectively]. Gadoliniumenhanced lesions and the size of affected vessels had no influence on functional status and were not included in the multivariate analysis.
Discussion
Our findings suggest a beneficial effect of maintenance therapy (especially AZA) after induction treatment in patients with PACNS after they have achieved remission. Patients who received maintenance therapy after induction treatment experienced fewer disease relapses and presented with fewer long-term disabilities than patients who did not receive it.
In the absence of prospective trials to guide the therapeutic management of PACNS, a combination of GC and another immunosuppressant (CYC in most patients) has been recommended to induce remission in severe cases, based on cohort studies [7, 10] . In systemic vasculitis, for which similar induction treatment is used, maintenance therapy with AZA, MTX, rituximab or MMF was shown to be useful in preventing relapses and to be GC-sparing [13, 1517] . However, few data exist on the usefulness or not of maintenance therapy in PACNS patients [18] . In the cohort from the Mayo Clinic, relapse rate was 27%. Only 17/72 (24%) of this cohort's patients treated initially with CYC received maintenance therapy and all remained FIG. 1 Percentage (with 95% CI) of good outcomes in patients with primary angiitis of the CNS Patients were distinguished on whether or not they received maintenance therapy. Good outcome was defined as survival without relapse and with good functional status (modified Rankin scale 4 2). *P < 0.05, **P < 0.01, ***P < 0.001.
www.rheumatology.oxfordjournals.org in remission, with a median follow-up of 12 months in the entire cohort [10] . When compared with the first description of our cohort [7] , follow-up has now been extended from 12 to 51 months. Relapse rate for the entire cohort is 33%; however, in the subgroup analyses, patients with maintenance had a lower relapse rate of 21% vs 41% in patients without maintenance. As in our first report [7] , we found here that patients with seizures and gadolinium-enhanced lesions on MRI at diagnosis suffered more frequent relapses and had small-vessel PACNS more often. In children with PACNS, seizures at onset were associated with progressive disease activity [19] and MMF showed a better maintenance effect compared with AZA [6, 18, 20] . In adult PACNS, MMF in combination with GC provided positive results in induction but has not been studied in maintenance [21] . In adults with AAV, MMF was less effective than AZA for maintaining disease remission [22] . In our adult PACNS patients, AZA was the most commonly used maintenance therapy, and only a few received MTX or MMF precluding any effectiveness comparisons.
Different therapeutic regimens have been debated for patients with PACNS according to the size of the affected vessels [7, 10, 19] . Whereas GC alone might be sufficient to treat adult patients with small-vessel PACNS, more aggressive treatments, including combinations of GC and another immunosuppressive agent, should be considered more systematically in those with large vessel PACNS [9, 10, 12] . However, now with a larger number of patients and longer follow-up (55 months vs 35 in our first report), we no longer observed such differences regarding functional status between patients with small-vessel or large-vessel PACNS. Moreover, we found that patients with isolated small-vessel PACNS are more prone to relapse than other patients.
The initial severity of the disease also influences disease course and outcomes. A high mRS before starting any treatment was an independent factor associated with poor functional status at last follow-up but was protective against relapses. The GC regimen and its specifications might also affect outcomes. However, >80% of our patients received relatively homogeneous treatment with a combination of GC and CYC; the small sample of patients treated with GC alone did not allow us to detect any prognostic differences in this subgroup. Optimal duration of GC has not been evaluated in PACNS. Our patients received GC for nearly 2 years, which is twice as long as in the Mayo Clinic cohort [10] . When comparing patients with or without maintenance therapy, the daily GC doses at 6, 12 and 18 months were lower in patients receiving maintenance but not at 24 months and last follow-up, and the duration of GC intake did not differ between groups. Long-term administration of GC in our cohort, in patient subgroups receiving maintenance treatment or not, may also have played a role in limiting relapses and functional declines. The optimal GC regimen remains to be determined for PACNS patients.
We observed 8 (7%) deaths in the entire cohort of 109 patients, which is half that observed in the cohort by Salvarani et al. [10] . Half of these patients died within a few weeks of severe disease onset and did not achieve remission despite induction treatment; the others died following relapse. This small number of deaths in our cohort did not allow us to further assess the possible effect of maintenance therapy (and other factors) on survival. Salvarani et al. observed increased mortality in patients that were older at the time of diagnosis and/or with infarctions on the MRI scan, which is a factor also associated with a poor response to treatment. Conversely, gadolinium-enhanced lesions may be associated with increased survival [10] .
Our study has notable strengths, but of course also some limitations. Whereas the partially retrospective and non-randomized design of our study might be seen as a www.rheumatology.oxfordjournals.org limitation, updated information was obtained for each patient and information on therapeutic management and outcomes was collected for all of them, with long-term follow-up exceeding 4 years. However, some information is lacking such as socio-economic status, the duration of symptoms before diagnosis or access to care centres. Treatment was not standardized, resulting in different GC tapering schedules, induction and maintenance regimens. We did not observe any major differences in induction treatments between the different groups. In addition, patients who received maintenance therapy did not show different disease presentations and mRS was no more severe at onset, thereby limiting biases due to differences in disease severity at diagnosis. In our cohort, maintenance therapy was prescribed based on the standard practice of physicians treating PACNS. Among the 30 patients from Internal Medicine, 24 (80%) received two-step treatment as in ANCA-associated vasculitis: induction and maintenance once remission was achieved. In the 67 patients from Neurology, only 24 (36%) received maintenance after induction. Disease severity was not different in patients according to the department they came from (i.e. Neurology or Internal Medicine). We acknowledge that mRS might not be the ideal marker for assessing functional status and was calculated retrospectively, before treatment, in most patients. The National Institute of Health Stroke Score could have been more effective as a tool for assessing functional status, but was available only for a few patients. Finally, the relatively low rate of biopsy-proven PACNS could be considered as another drawback of our study. However, this low rate does not differ from the other adult cohort published (36% in Mayo Clinic's cohort [10] ) and emphasizes the fact that, despite being recognized as carrying the best diagnostic value, brain biopsy is not systematically performed in routine practice and is not as sensitive as often, mistakenly, believed [23, 24] .
In conclusion, our findings indicate that maintenance therapy (especially AZA) should probably be given to adult patients with PACNS once remission has been achieved (most usually with high-dose GC and CYC). Such maintenance therapy decreases long-term disability and the risk of disease relapse. Further prospective and international trials are required to confirm these findings and to help determine the best treatment agents and durations. Disclosure statement: C.P. has consulted for and/or had speaker fees from Hofman-LaRoche (<5000 CAD), Sanofi (<5000 CAD) and ChemoCEntryx (<5000 CAD). All other authors have declared no conflicts of interest.
